Drug Profile


Alternative Names: Equa; Galvus; Jalra; LAF 237; LAF 237A; NVP LAF 237; NVP LAF 237A; Xiliarx

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Hanmi Pharmaceutical; Novartis; Samsung Medical Center; University of Sao Paulo
  • Class Antihyperglycaemics; Cycloparaffins; Nitriles; Polycyclic bridged compounds; Pyrrolidines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Type 1 diabetes mellitus

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Aug 2017 Novartis completes a phase II trial in Type-2 diabetes mellitus (Combination therapy) in South Korea (PO) (NCT01404676)
  • 29 May 2017 Discontinued - Phase-II/III for Type-2 diabetes mellitus (Treatment-naive) in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top